TY - JOUR
T1 - Biological Age Acceleration and Motoric Cognitive Risk Syndrome
AU - Sathyan, Sanish
AU - Ayers, Emmeline
AU - Adhikari, Dristi
AU - Gao, Tina
AU - Milman, Sofiya
AU - Barzilai, Nir
AU - Verghese, Joe
N1 - Funding Information:
Our findings were replicated in the HRS, a nationally representative USA‐based cohort study of sociodemographic, economic, and psychosocial measures in individuals aged 50 years and older since 1992. For the present analysis, participants aged 65 years and older were included. The HRS is supported by the National Institute on Aging (NIA U01AG009740) and Social Security Administration, and is conducted at the University of Michigan. In 2016, as part of the HRS venous blood study, DNA methylation assays were done on a nonrandom sample of 4,018 individuals. We have previously reported the epidemiology of MCR in HRS. Racial distribution of HRS includes 82.0% Caucasian, 12.6% African American, and 5.4% others. 22 6,18,23
Funding Information:
This work was supported by grants from the NIH, National Institute of Aging (R01AG057548, J.V.; R56AG044829, S.M. and J.V.; P01AG021654, N.B.; R01AG046949, N.B.; R01AG057909, N.B.; R01AG061155, S.M.), Nathan Shock Center of Excellence for the Biology of Aging (P30AG038072, N.B.), American Federation for Aging Research (S.M.), and Glenn Center for the Biology of Human Aging Paul Glenn Foundation Grant (N.B.). The HRS was supported by an NIH National Institute on Aging grant (1R56AG057548‐01). The sponsors had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2023 American Neurological Association.
PY - 2023
Y1 - 2023
N2 - Objective: Motoric cognitive risk (MCR) syndrome, a predementia syndrome characterized by slow gait and subjective cognitive concerns, is associated with multiple age-related risk factors. We hypothesized that MCR is associated with biological age acceleration. We examined the associations of biological age acceleration with MCR, and mortality risk in MCR cases. Methods: Biological age was determined using proteomic and epigenetic clocks in participants aged 65 years and older in the LonGenity study (N = 700, females = 57.9%) and Health and Retirement Study (HRS; N = 1,043, females = 57.1%) cohorts. Age acceleration (AgeAccel) was operationally defined as the residual from regressing predicted biological age (from both clocks separately) on chronological age. Association of AgeAccel with incident MCR in the overall sample as well as with mortality risk in MCR cases was examined using Cox models and reported as hazard ratios (HRs). Results: AgeAccel scores derived from a proteomic clock were associated with prevalent MCR (odds ratio adjusted for age, gender, education years, and chronic illnesses [aOR] = 1.36, 95% confidence interval [CI] = 1.09–1.71) as well as predicted incident MCR (HR = 1.19, 95% CI = 1.00–1.41) in the LonGenity cohort. In HRS, the association of AgeAccel using an epigenetic clock with prevalent MCR was confirmed (aOR = 1.47, 95% CI = 1.16–1.85). Participants with MCR and accelerated aging (positive AgeAccel score) were at the highest risk for mortality in both LonGenity (HR = 3.38, 95% CI = 2.01–5.69) and HRS (HR = 2.47, 95% CI = 1.20–5.10). Interpretation: Accelerated aging predicts risk for MCR, and is associated with higher mortality in MCR patients. ANN NEUROL 2023.
AB - Objective: Motoric cognitive risk (MCR) syndrome, a predementia syndrome characterized by slow gait and subjective cognitive concerns, is associated with multiple age-related risk factors. We hypothesized that MCR is associated with biological age acceleration. We examined the associations of biological age acceleration with MCR, and mortality risk in MCR cases. Methods: Biological age was determined using proteomic and epigenetic clocks in participants aged 65 years and older in the LonGenity study (N = 700, females = 57.9%) and Health and Retirement Study (HRS; N = 1,043, females = 57.1%) cohorts. Age acceleration (AgeAccel) was operationally defined as the residual from regressing predicted biological age (from both clocks separately) on chronological age. Association of AgeAccel with incident MCR in the overall sample as well as with mortality risk in MCR cases was examined using Cox models and reported as hazard ratios (HRs). Results: AgeAccel scores derived from a proteomic clock were associated with prevalent MCR (odds ratio adjusted for age, gender, education years, and chronic illnesses [aOR] = 1.36, 95% confidence interval [CI] = 1.09–1.71) as well as predicted incident MCR (HR = 1.19, 95% CI = 1.00–1.41) in the LonGenity cohort. In HRS, the association of AgeAccel using an epigenetic clock with prevalent MCR was confirmed (aOR = 1.47, 95% CI = 1.16–1.85). Participants with MCR and accelerated aging (positive AgeAccel score) were at the highest risk for mortality in both LonGenity (HR = 3.38, 95% CI = 2.01–5.69) and HRS (HR = 2.47, 95% CI = 1.20–5.10). Interpretation: Accelerated aging predicts risk for MCR, and is associated with higher mortality in MCR patients. ANN NEUROL 2023.
UR - http://www.scopus.com/inward/record.url?scp=85150653332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150653332&partnerID=8YFLogxK
U2 - 10.1002/ana.26624
DO - 10.1002/ana.26624
M3 - Article
C2 - 36843279
AN - SCOPUS:85150653332
SN - 0364-5134
JO - Annals of Neurology
JF - Annals of Neurology
ER -